Key Updates in Myasthenia Gravis From AANEM 2025 - Medscape
Myasthenia gravis updates from AANEM 2025 include efficacy data for efgartigimod, telitacicept, and gefurulimab, plus interim results for a CAR T-cell therapy and DNTH10, an active C1S inhibitor.
New Hope for Hard-to-Treat Myasthenia Gravis - Medscape
New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited and patients face persistent unmet clinical needs.
Myasthenia Gravis Treatment: 5 Things to Know - Medscape
Jun 28, 2024 · Myasthenia gravis (MG) is a rare, acquired autoimmune disorder of the neuromuscular junction, characterized by fatigable muscle weakness in the voluntary muscles. Most patients with …
AANEM 2025: Key Highlights in Myasthenia Gravis - Medscape
At the 2025 AANEM Annual Meeting, groundbreaking research was presented that advances the understanding and management of myasthenia gravis (MG), reports Dr Katherine Ruzhansky. One …
EMA Backs First FcRn Inhibitor for Myasthenia Gravis - Medscape
Sep 22, 2025 · In clinical trials, Imaavy plus standard therapy improved muscle strength and daily function in adults and adolescents with generalized myasthenia gravis.
FDA Approves Uplizna for Generalized Myasthenia Gravis - Medscape
Dec 15, 2025 · The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.
Myasthenia Gravis Med Tied to Major Reduction in Steroid Use
Nov 7, 2025 · 18-month data show patients with generalized myasthenia gravis taking efgartigimod were able to reduce glucocorticoids to low levels or discontinue them.
AANEM 2025: Previewing Innovations in Myasthenia Gravis - Medscape
Oct 22, 2025 · The upcoming 2025 AANEM Annual Meeting promises exciting updates in myasthenia gravis (MG) research, clinical care, and treatment innovation, reflecting significant progress over the …
Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis
Apr 10, 2025 · Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.
Durable Benefit for Nipocalimab in gMG Across Age Groups
Nov 7, 2025 · Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control for generalized myasthenia gravis in both teens and adults.